Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M15,355Revenue (TTM) $M1,184Net Margin (%)-47.4Altman Z-Score7.3
Enterprise Value $M15,368EPS (TTM) $-3.4Operating Margin %-62.7Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-64.7Higher ROA y-yN
Price/Book5.510-y EBITDA Growth Rate %--Quick Ratio2.9Cash flow > EarningsY
Price/Sales12.55-y EBITDA Growth Rate %182Current Ratio4.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-15.1Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-22.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M174ROIC % (ttm)-22.1Gross Margin Increase y-yN

Gurus Latest Trades with BMRN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

BMRN is held by these investors:

BMRN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BIENAIME JEAN JACQUESCEO 2017-05-24Sell5,000$88.38-0.43view
BIENAIME JEAN JACQUESCEO 2017-05-17Sell5,000$91.73-4.07view
BIENAIME JEAN JACQUESCEO 2017-05-12Sell5,000$89.23-1.38view
BIENAIME JEAN JACQUESCEO 2017-05-08Sell10,000$96.09-8.42view
Mueller BrianSVP, Corporate Controller 2017-05-08Sell7,482$91.87-4.21view
Ajer Jeffrey RobertEVP, Chief Commercial Officer 2017-05-05Sell4,486$99-11.11view
Davis George EricEVP, General Counsel 2017-05-05Sell2,500$100.34-12.3view
Ajer Jeffrey RobertEVP, Chief Commercial Officer 2017-05-02Sell302$96.74-9.03view
BIENAIME JEAN JACQUESCEO 2017-04-27Sell5,000$95.72-8.07view
BIENAIME JEAN JACQUESCEO 2017-04-25Sell5,000$94-6.38view

Press Releases about BMRN :

Quarterly/Annual Reports about BMRN:

News about BMRN:

Articles On GuruFocus.com
BioMarin to Attend Two Upcoming Investor Conferences May 02 2017 
FDA Approves Brineura™ (cerliponase alfa) for the Treatment of CLN2 Disease, a Form of Batten Dise Apr 27 2017 
BioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase alfa) for First Treat Apr 21 2017 
BioMarin to Host First Quarter 2017 Financial Results Conference Call and Webcast on Thursday, May 4 Apr 20 2017 
BioMarin Announces Kuvan® (sapropterin dihydrochloride) Patent Challenge Settlement Apr 13 2017 
Piotroski F-Score in the Real World Dec 19 2016 
U.S. Elections: What They Might Mean for Investors - JOHCM Commentary Nov 29 2016 
Low Valuation Ratios Lead to Strong Portfolio Returns Sep 13 2016 
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 
Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 

More From Other Websites
Ultragenyx Receives Priority Review for rhGUS from FDA May 24 2017
Why Sangamo Therapeutics Inc. Jumped Higher Today May 12 2017
Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death May 10 2017
BioMarin Pharmaceutical Inc. Moves Toward Profitability May 09 2017
Edited Transcript of BMRN earnings conference call or presentation 4-May-17 8:30pm GMT May 09 2017
BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : May... May 09 2017
BioMarin: Is Profitability On The Horizon? May 08 2017
These Biotechs Are Grabbing Bullish Views In Wake Of Earnings May 05 2017
BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up May 05 2017
BioMarin reports 1Q loss May 04 2017
BioMarin Announces First Quarter 2017 Financial Results May 04 2017
Investor Network: BioMarin Pharmaceutical Inc. to Host Earnings Call May 04 2017
[$$] Did Gilead Cut Buybacks for Acquisition? May 04 2017
Why Earnings Season Could Be Great for BioMarin (BMRN) May 03 2017
BioMarin to Attend Two Upcoming Investor Conferences May 02 2017
BioMarin CEO says 'the system will have to determine' the... Apr 28 2017
BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug Apr 28 2017
Today's Research Reports on Biotech Stocks to Watch: Pacific Biosciences of California and BioMarin... Apr 28 2017
BioMarin wins FDA approval for life-changing drug for kids — with a $700,000-per-year cost Apr 27 2017
BioMarin Prices Orphan Drug at $702,000, Promises Big Discounts Apr 27 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)